The R's of Radiotherapy

Radiotherapy is a crucial cancer treatment that utilizes high-energy radiation to shrink tumors and kill cancer cells. Understanding the biological responses of cells and tissues to this radiation is vital for optimizing treatment plans. These responses are often summarized as "The R's of Radiotherapy," a set of key radiobiological principles that have evolved over time from four to six core concepts.

The Fundamental R's of Radiotherapy: An Overview

Initially, four fundamental biological phenomena were identified as crucial in determining the outcome of fractionated radiotherapy. These principles help explain how radiation affects both cancerous and healthy cells, guiding clinical strategies to maximize tumor control while minimizing damage to normal tissues. Over time, further understanding led to the inclusion of additional 'R's, expanding our comprehensive view.

The Original 4 R's of Radiotherapy

The foundational principles are:

• Recovery from Sublethal Damage (RSLD): Cells' ability to repair non-lethal damage between radiation doses.
• Redistribution within the Cell Cycle: Changes in the cell population's distribution across different cell cycle phases, affecting overall radiosensitivity.
• Reoxygenation of the Tumor: The process by which hypoxic (oxygen-deprived) tumor cells regain oxygenation, becoming more radiosensitive.
• Repopulation of Cells: The proliferation of tumor cells and normal cells during and after a course of radiotherapy.

Expanding to the 5 R's of Radiotherapy

As research progressed, a fifth 'R' was added, recognizing an intrinsic cellular characteristic:

• Radiosensitivity: The inherent susceptibility of cells to damage by radiation.

The Modern 6 R's of Radiotherapy

More recently, the critical role of the body's defense system has been acknowledged, leading to the inclusion of a sixth 'R':

• Reactivation of the Immune Response: The stimulation of the immune system by radiation to target and eliminate cancer cells.

Understanding Recovery from Radiation Damage

Cells possess remarkable mechanisms to repair damage induced by radiation. This repair capacity is a major factor in determining the effectiveness of radiotherapy and necessitates fractionated dosing schedules.

Recovery from Sublethal Damage (RSLD)

Recovery from sublethal damage (RSLD), sometimes referred to as "split-dose recovery" or "Elkind recovery," is the ability of cells to repair damage that, if accumulated, would be lethal. This process occurs between fractions of radiation doses.

• When cells are irradiated with a first dose, and then a second dose after a delay of a few hours, the survivors of the first dose react like unirradiated cells, showing enhanced survival compared to receiving both doses simultaneously.
• This repair is crucial in allowing normal tissues to recover between fractions, reducing their overall damage while still delivering a high cumulative dose to the tumor.
• Dose fractionation exploits this by repeating the shoulder of the cell survival curve multiple times, making the effective dose-survival curve linear and increasing cell killing for the same total dose compared to a single large dose.
• The extent of repair can vary, with factors like dose rate also influencing it. At lower dose rates, cells have more time to repair damage, leading to decreased cell killing.

Recovery from Potentially Lethal Damage (RPLD)

Potentially lethal damage (PLD) refers to damage that can be repaired if cells are maintained under specific, non-dividing conditions after irradiation. If cells are allowed time in a stationary phase after irradiation, their survival is enhanced.

• Studies show that if cells are left in a stationary phase for 6 to 12 hours after irradiation before being subcultured, cell survival increases significantly. This suggests repair of PLD.
• In in vivo models, such as mouse fibrosarcomas, allowing an interval between tumor irradiation and removal for colony formation also demonstrates increased cell survival due to PLD repair.

Redistribution within the Cell Cycle and Radiosensitivity

Cells are not uniformly sensitive to radiation throughout their life cycle. Their position in the cell cycle significantly influences their radiosensitivity, a phenomenon known as cell cycle dependence of radiosensitivity.

Cell Cycle Dependence

• The duration of cell cycle phases varies: G1 can be 0 to many hundreds of hours, S phase around 8 hours, G2 around 4-6 hours, and M phase around 1 hour.
• Cells in mitosis (M phase) are typically the most sensitive to radiation, showing a steep survival curve with no shoulder.
• Cells in late S phase are generally the most resistant, characterized by a shallower survival curve with a large initial shoulder.
• G1 and early S phases exhibit intermediate sensitivity.

The Impact of Redistribution

Redistribution refers to the selective killing of cells in more sensitive phases by a radiation dose, leading to a synchronization of the surviving cell population into more resistant phases. Between fractions, these surviving cells may then progress into sensitive phases, becoming targets for subsequent doses.

• An initial radiation fraction preferentially kills sensitive cells (e.g., late G1 and G2-phase cells).
• The more resistant S-phase cells survive better and continue to move through the cell cycle.
• If the next radiation fraction is delivered when a large proportion of these surviving cells have moved into a sensitive phase (like G2 or M), the overall sensitivity of the population to the second dose increases.
• This effect is complicated by radiation-induced cell cycle delays, making the behavior of individual tumors difficult to predict.

Inherent Radiosensitivity

Radiosensitivity refers to the intrinsic susceptibility of a cell line to radiation-induced damage. This varies widely among different cell types and even among different human tumors.

• Survival curves for various cell lines show a broad range of radiosensitivity, particularly in the size of the shoulder region, with some neuroblastoma cell lines being highly sensitive and some mouse cells being highly resistant.
• Interestingly, while asynchronous cultures show wide variation, the radiosensitivity of mitotic cells is quite similar across different cell lines.
• High dose rate (HDR) and low dose rate (LDR) exposures also highlight differences in radiosensitivity. At LDR, survival curves fan out, indicating a range of inherent radiosensitivities and varying repair times for sublethal damage among cells.
• Cell lines that exhibit prominent DNA "laddering" (a characteristic of apoptotic death) after irradiation tend to be more radiosensitive.

Reoxygenation of Tumors

Oxygen plays a critical role in enhancing the effectiveness of radiation, a phenomenon known as the radiobiological oxygen effect.

• Oxygen stabilizes free radicals produced by radiation, making DNA damage more permanent and thus increasing cell killing.
• Hypoxic cells require more radiation to be killed compared to well-oxygenated (aerated) cells.
• Tumors often contain hypoxic areas due to rapid growth exceeding blood supply or temporary constriction of blood vessels.
• Tumor shrinkage following an initial radiation dose can decrease these hypoxic areas by improving oxygen delivery, which then reinforces the effect of subsequent fractions.

The Process of Reoxygenation

Reoxygenation is the process by which hypoxic tumor cells become re-oxygenated after a dose of radiation. This is crucial for fractionated radiotherapy because it allows previously resistant hypoxic cells to become more sensitive for subsequent doses.

• After an x-ray dose, a greater proportion of aerated cells are killed, leaving a higher percentage of hypoxic cells.
• However, due to improved blood flow, reduced tumor volume, or changes in oxygen consumption, the tumor tends to reoxygenate, and the pre-irradiation pattern of oxygenation tends to return over time.
• The extent and rapidity of reoxygenation are highly variable and difficult to predict across different tumor types.
• For example, mouse mammary carcinoma reoxygenates rapidly, while some osteosarcomas may reoxygenate slowly or not at all for several days.

Clinical Implications of Reoxygenation

Due to the unpredictable nature of reoxygenation, strategies to overcome hypoxia have been explored:

• Hypoxic cell sensitizers (substances mimicking oxygen's effects) or hyperbaric oxygen have shown effectiveness in some experimental tumors, but generally have not been consistently effective in clinical trials.
• Variable results may arise because some tumor cells respond differently to short-term versus chronic hypoxia, with reoxygenation enhancing sensitivity even in chronically hypoxic cells.

Repopulation of Cells

Repopulation refers to the proliferation of cancer cells (and normal cells) between radiation fractions, especially during treatment breaks (e.g., over weekends in a typical 5x weekly schedule).

• Rapidly proliferating tumors repopulate faster, necessitating careful scheduling.
• With longer overall treatment times, greater total doses may be required to achieve tumor control, as more repopulation must be compensated for.
• This phenomenon is a key reason for the development of accelerated treatment schedules (same total dose in shorter time) or hyperfractionation (two smaller doses per day instead of one larger dose) to combat tumor repopulation.
• However, these accelerated schedules must also consider their potential impact on normal tissue toxicity.
• Studies have observed that the dose required for local control in 50% of cases (TCD₅₀) increases with overall treatment time for squamous cell tumors, illustrating the effect of accelerated repopulation.
• While historically correlated with treatment duration, some analyses suggest that the observed increase in TCD₅₀ might indirectly reflect "dose-time prescription habits" rather than solely accelerated repopulation, as higher total doses naturally require more time to be applied.

Reactivation of the Immune Response

The immune system plays a critical role in fighting cancer, and radiation therapy can actively engage and enhance this immune response. This is the newest 'R' to be formally recognized.

• Cell lysis caused by radiation treatment leads to the release of damaged DNA debris and tumor-associated antigens (TAA) into the cell cytosol and extracellular space.
• Dendritic cells (DC), which are antigen-presenting cells (APCs), take up and process these released debris and antigens.
• These activated dendritic cells can then prime cytotoxic T cells to recognize and target the tumor antigens. Naïve T-cells become active T-effector cells with specific reactivity towards the tumor.
• T-effector cells migrate to the tumor and kill tumor cells, which in turn can release more TAA, leading to further amplification of the immune system signals.

Local vs. Systemic Immune Response

• Single-site radiotherapy can induce a potential anti-tumor immune response from infiltrating T-cells at the irradiated site.
• Multiple-site radiotherapy may lead to a greater potential for an anti-tumor immune response from a more diverse repertoire of infiltrating T-cells, potentially targeting non-irradiated tumor sites (the abscopal effect).

Frequently Asked Questions about The R's of Radiotherapy

What are the 6 R's of Radiotherapy?

The 6 R's of Radiotherapy are: Recovery from sublethal damage, Redistribution within the cell cycle, Reoxygenation of the tumor, Repopulation of cells, Radiosensitivity, and Reactivation of the immune response. These principles describe how cells and tumors respond to radiation treatment.

Why are The R's of Radiotherapy important for treatment planning?

Understanding The R's is crucial for optimizing radiotherapy treatment plans. They help clinicians determine the optimal dose per fraction, total dose, and overall treatment time to maximize cancer cell killing while minimizing damage to healthy tissues. For example, fractionated doses exploit recovery of normal tissues and reoxygenation of tumors.

How does redistribution affect tumor sensitivity in radiotherapy?

Redistribution affects tumor sensitivity because cells have varying radiosensitivity depending on their phase in the cell cycle. Radiation preferentially kills sensitive cells, causing a shift in the surviving population towards more resistant phases. Over time, these resistant cells progress into sensitive phases, becoming more vulnerable to subsequent radiation doses, which can be exploited with proper timing between fractions.

What is the difference between sublethal and potentially lethal damage recovery?

Recovery from sublethal damage (RSLD) refers to a cell's ability to repair damage between two radiation doses, typically occurring within hours, allowing it to survive an otherwise lethal cumulative dose. Recovery from potentially lethal damage (RPLD) refers to damage that can be repaired if cells are held in a non-dividing state (e.g., stationary phase) for several hours after irradiation, preventing the expression of the damage as cell death.

Can radiotherapy boost the body's immune system?

Yes, radiotherapy can boost the body's immune system. Radiation damages tumor cells, causing them to release tumor-associated antigens and other debris. These are picked up by antigen-presenting cells (like dendritic cells), which then activate T-cells to specifically target and destroy cancer cells, potentially even at non-irradiated sites.